The main causes of death in patients with chronic kidney disease (CKD) are of
cardiovascular nature. The interaction between traditional cardiovascular risk factors (CVRF) …

Introduction: Antiplatelet therapy represents a key strategy for the prevention of thrombotic
complications in patients with both acute and chronic coronary syndromes, particularly those …

Aims The aim of this study was to assess the impact of chronic kidney disease (CKD) on the
safety and efficacy of ticagrelor monotherapy among patients undergoing percutaneous …

Background: In patients with acute coronary syndrome (ACS) with a high risk of ischemia,
the impact of ticagrelor monotherapy after short-term dual antiplatelet therapy (DAPT) has …

Post-contrast acute kidney injury (PC-AKI) is a common complication after percutaneous
coronary intervention (PCI). However, it is unclear whether or not the effects of PC-AKI on …

Background Antiplatelet agents are widely used to prevent cardiovascular events. The risks
and benefits of antiplatelet agents may be different in people with chronic kidney disease …

Chronic kidney disease patients are at increased risk of cardiovascular disease, which is the
leading cause of mortality among this population. In addition, chronic kidney disease is a …

Patients suffering from chronic kidney disease (CKD) have higher ischemic and bleeding
risk compared with patients with normal renal function. The aim of our systematic review and …

Abstract Background Complex Revascularisation in High-Risk Indicated Patients (CHIP) is
emerging in Percutaneous Coronary Intervention (PCI). We document the frequency and …

Background Conflicting evidence exists to support whether short duration of dual antiplatelet
therapy (DAPT) followed by P2Y12 inhibitor monotherapy reduces bleeding complications …